Diabetic neuropathy: pathogenetic background, current and future therapies

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2001-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737175.1.2.225PMID 19811034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.

  2009cited by this paper
• Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials.

  2009cited by this paper
• Nerve ischaemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models

  2004cited by this paper
• GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.

  2002cited by this paper
• C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat

  2001cited by this paper
• Altered Immediate Early Gene Expression in Injured Diabetic Nerve: Implications in Regeneration

  2001cited by this paper
• Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician

  2001cited by this paper
• Molecular basis for the insulinomimetic effects of C-peptide

  2001cited by this paper
• Pathophysiology of oxidative stress in diabetes mellitus.

  2001cited by this paper
• Insulin receptor in rat peripheral nerve: its localization and alternatively spliced isoforms

  2000cited by this paper
• A comparison of diabetic polyneuropathy in Type II diabetic BBZDR/Wor rats and in Type I diabetic BB/Wor rats

  2000cited by this paper
• Diabetic neuropathy – a continuing enigma

  2000cited by this paper
• Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy.

  2000cited by this paper
• Role of C-peptide in human physiology.

  2000cited by this paper
• Effects of DL-a-Lipoic Acid on Peripheral Nerve Conduction, Blood Flow, Energy Metabolism, and Oxidative Stress in Experimental Diabetic Neuropathy

  2000cited by this paper
• Beneficial effects of C‐peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus

  2000cited by this paper
• Brain ischemia and reperfusion: molecular mechanisms of neuronal injury.

  2000cited by this paper
• Neurotrophic factors in the therapy of diabetic neuropathy.

  1999cited by this paper
• The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy.

  1999cited by this paper
• Diabetic neuropathy--the utility of nerve biopsy.

  1999cited by this paper
• C-peptide induces a concentration-dependent dilation of skeletal muscle arterioles only in presence of insulin.

  1999cited by this paper
• Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy.

  1999cited by this paper
• New insights into the pathogenesis of diabetic neuropathy.

  1999cited by this paper
• Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.

  1999cited by this paper
• Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

  1999cited by this paper
• Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli

  1999cited by this paper
• Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.

  1999cited by this paper
• Growth Factors and Taurine Protect against Excitotoxicity by Stabilizing Calcium Homeostasis and Energy Metabolism

  1999cited by this paper
• Diabetic neuropathy--the utility of nerve biopsy.

  1999cited by this paper
• Experimental diabetic neuropathy: an update

  1999cited by this paper
• Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury

  1999cited by this paper
• Effects of 3‐week oral treatment with the antioxidant thioctic acid (α‐lipoic acid) in symptomatic diabetic polyneuropathy

  1999cited by this paper
• alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes.

  1999cited by this paper
• Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. Ponalrestat Study Group.

  1998cited by this paper
• Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy.

  1998cited by this paper
• Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy

  1998cited by this paper
• A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats

  1998cited by this paper
• Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene

  1998cited by this paper
• Near nerve local insulin prevents conduction slowing in experimental diabetes.

  1997cited by this paper
• Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort

  1997cited by this paper
• Importance of Cerebral Blood Flow to the Recognition of and Physiological Responses to Hypoglycemia

  1997cited by this paper
• Advanced Glycation End Product-Induced Activation of NF-κB is Suppressed by α-Lipoic Acid in Cultured Endothelial Cells

  1997cited by this paper
• Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus

  1997cited by this paper
• Identification and Characterization of Multiple Osmotic Response Sequences in the Human Aldose Reductase Gene*

  1997cited by this paper
• Neuropathology of diabetic neuropathy and its correlations with neurophysiology.

  1997cited by this paper
• Essential Fatty Acids in the Management of Impaired Nerve Function in Diabetes

  1997cited by this paper
• Aldose Reductase Inhibitors: The End of an Era or the Need for Different Trial Designs?

  1997cited by this paper
• Regulation of gene expression by hypertonicity.

  1997cited by this paper
• Neuropathology of diabetic neuropathy and its correlations with neurophysiology.

  1997cited by this paper
• Classification, Differential Diagnosis, and Staging of Diabetic Peripheral Neuropathy

  1997cited by this paper
• Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans

  1997cited by this paper
• Prevention of vascular and neural dysfunction in diabetic rats by C-peptide.

  1997cited by this paper
• Metabolic and Vascular Factors in the Pathogenesis of Diabetic Neuropathy

  1997cited by this paper
• Peripheral nerve energy metabolism in experimental diabetic neuropathy

  1997cited by this paper
• A Multicenter Study on the Prevalence of Diabetic Neuropathy in Italy

  1997cited by this paper
• Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats.

  1997cited by this paper
• The assessment of diabetic polyneuropathy in daily clinical practice: Reproducibility and validity of Semmes Weinstein monofilaments examination and clinical neurological examination

  1997cited by this paper
• Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.

  1996cited by this paper
• Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase.

  1996cited by this paper
• Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat.

  1996cited by this paper
• N-Acetylated alpha-linked acidic dipeptidase may be involved in axon-Schwann cell signalling

  1996cited by this paper
• Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats.

  1996cited by this paper
• Design of Controlled Clinical Trials for Diabetic Polyneuropathy

  1996cited by this paper
• Involvement of increased excitatory amino acids and intracellular Ca2+ concentration in the spinal dorsal horn in an animal model of neuropathic pain

  1996cited by this paper
• Characterization of the osmotic response element of the human aldose reductase gene promoter.

  1996cited by this paper
• Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat.

  1996cited by this paper
• The Antioxidant α-Lipoic Acid Enhances Insulin-Stimulated Glucose Metabolism in Insulin-Resistant Rat Skeletal Muscle

  1996cited by this paper
• Involvement of increased excitatory amino acids and intracellular Ca[2+] concentration in the spinal dorsal horn in an animal model of neuropathic pain(Neuropathic painにおける脊髄後角興奮性アミノ酸および細胞内カルシウムイオン濃度の検討)

  1996cited by this paper
• Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated α-Linked Acidic Dipeptidase.

  1996cited by this paper
• Peripheral nerve regeneration.

  1996cited by this paper
• Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study).

  1995cited by this paper
• Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux

  1995cited by this paper
• An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients.

  1995cited by this paper
• Lipoic Acid Improves Nerve Blood Flow, Reduces Oxidative Stress, and Improves Distal Nerve Conduction in Experimental Diabetic Neuropathy

  1995cited by this paper
• GLUTAMATE‐INDUCED CALCIUM LOADS: EFFECTS ON ENERGY METABOLISM AND NEURONAL VIABILITY

  1995cited by this paper
• Pathological Definition and Evaluation of Diabetic Neuropathy and Clinical Correlations

  1994cited by this paper
• Reduced insulin-like growth factor-I mRNA content in liver, adrenal glands and spinal cord of diabetic rats

  1994cited by this paper
• Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor.

  1994cited by this paper
• The effect of prostaglandin E1.alpha CD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy.

  1994cited by this paper
• A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy

  1994cited by this paper
• Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients.

  1994cited by this paper
• Lack of neurotrophin-3 leads to deficiencies in the peripheral nervous system and loss of limb proprioceptive afferents.

  1994cited by this paper
• Nerve growth factor administration protects against experimental diabetic sensory neuropathy.

  1994cited by this paper
• Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat

  1993cited by this paper
• Hyperglycemic Pseudohypoxia and Diabetic Complications

  1993cited by this paper
• Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group.

  1993cited by this paper
• Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.

  1993cited by this paper
• Treatment of Diabetic Neuropathy With γ-Linolenic Acid

  1993cited by this paper
• Tolrestat for Mild Diabetic Neuropathy: A 52-Week, Randomized, Placebo-Controlled Trial

  1993cited by this paper
• Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1.

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Overt Diabetic Neuropathy: Repair of Axo‐glial Dysjunction and Axonal Atrophy by Aldose Reductase Inhibition and its Correlation to Improvement in Nerve Conduction Velocity

  1993cited by this paper
• Association of Erythrocyte Aldose Reductase Activity with Diabetic Complications in Type 1 Diabetes Mellitus

  1993cited by this paper
• A Placebo‐controlled Double‐blind Study of Epalrestat (ONO‐2235) in Patients with Diabetic Neuropathy

  1993cited by this paper
• Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers.

  1993cited by this paper
• Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.

  1993cited by this paper
• A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.

  1992cited by this paper
• Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats

  1992cited by this paper
• Diabetic Neuropathies

  1992cited by this paper
• Complications: Neuropathy, Pathogenetic Considerations

  1992cited by this paper

• Peripheral Neuropathy Presents Similar Symptoms and Pathological Changes in Both High-Fat Diet and Pharmacologically Induced Pre- and Diabetic Mouse Models

  2021cites this paper
• Assessment of the Effect of C-Peptide Level on Na-K ATPase Activity In Individuals with Type II Diabetic Peripheral Neuropathy

  2021cites this paper
• L-carnitine ameliorates peripheral neuropathy in diabetic mice with a corresponding increase in insulin‑like growth factor‑1 level.

  2018cites this paper
• Effect of streptozotocin-induced type I diabetes mellitus on the cardiac conduction system of the rat heart

  2016cites this paper
• Положительное влияние ацетил-L-карнитина на болевой синдром, регенерацию нервов и вибрационное чувство у пациентов с хронической диабетической нейропатией. Анализ результатов двух рандомизированных плацебоконтролируемых исследований

  2015cites this paper
• A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus.

  2009cites this paper
• The heterogeneity of diabetic neuropathy.

  2008cites this paper
• The Effects of C-peptide on Type 1 Diabetic Polyneuropathies and Encephalopathy in the BB/Wor-rat

  2008cites this paper
• Diabetic Neuropathy Differs in Type 1 and Type 2 Diabetes

  2006cites this paper
• NAAG peptidase inhibitors and their potential for diagnosis and therapy

  2005cites this paper
• Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials.

  2005cites this paper
• Type 1 Diabetic Neuropathy and C-peptide

  2004influential citation
• C-peptide and diabetic neuropathy

  2003cites this paper